vs
Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and Merck & Co. (MRK). Click either name above to swap in a different company.
Merck & Co. is the larger business by last-quarter revenue ($16.4B vs $14.5B, roughly 1.1× ASTRAZENECA PLC). Merck & Co. runs the higher net margin — 18.1% vs 16.9%, a 1.1% gap on every dollar of revenue. On growth, ASTRAZENECA PLC posted the faster year-over-year revenue change (11.7% vs 5.0%).
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
AZN vs MRK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.5B | $16.4B |
| Net Profit | $2.4B | $3.0B |
| Gross Margin | 82.9% | 66.2% |
| Operating Margin | 24.3% | 20.9% |
| Net Margin | 16.9% | 18.1% |
| Revenue YoY | 11.7% | 5.0% |
| Net Profit YoY | 27.0% | -20.8% |
| EPS (diluted) | $1.57 | $1.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $16.4B | ||
| Q3 25 | — | $17.3B | ||
| Q2 25 | $14.5B | $15.8B | ||
| Q1 25 | — | $15.5B | ||
| Q4 24 | — | $15.6B | ||
| Q3 24 | — | $16.7B | ||
| Q2 24 | $12.9B | $16.1B | ||
| Q1 24 | — | $15.8B |
| Q4 25 | — | $3.0B | ||
| Q3 25 | — | $5.8B | ||
| Q2 25 | $2.4B | $4.4B | ||
| Q1 25 | — | $5.1B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | $1.9B | $5.5B | ||
| Q1 24 | — | $4.8B |
| Q4 25 | — | 66.2% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | 82.9% | 77.5% | ||
| Q1 25 | — | 78.0% | ||
| Q4 24 | — | 75.5% | ||
| Q3 24 | — | 75.5% | ||
| Q2 24 | 83.1% | 76.8% | ||
| Q1 24 | — | 77.6% |
| Q4 25 | — | 20.9% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | 24.3% | 31.6% | ||
| Q1 25 | — | 38.0% | ||
| Q4 24 | — | 26.7% | ||
| Q3 24 | — | 24.6% | ||
| Q2 24 | 21.2% | 37.3% | ||
| Q1 24 | — | 35.9% |
| Q4 25 | — | 18.1% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | 16.9% | 28.0% | ||
| Q1 25 | — | 32.7% | ||
| Q4 24 | — | 24.0% | ||
| Q3 24 | — | 19.0% | ||
| Q2 24 | 14.9% | 33.9% | ||
| Q1 24 | — | 30.2% |
| Q4 25 | — | $1.19 | ||
| Q3 25 | — | $2.32 | ||
| Q2 25 | $1.57 | $1.76 | ||
| Q1 25 | — | $2.01 | ||
| Q4 24 | — | $1.49 | ||
| Q3 24 | — | $1.24 | ||
| Q2 24 | $1.24 | $2.14 | ||
| Q1 24 | — | $1.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1B | $14.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8B | $52.6B |
| Total Assets | $112.4B | $136.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.6B | ||
| Q3 25 | — | $18.2B | ||
| Q2 25 | $7.1B | $8.6B | ||
| Q1 25 | — | $9.2B | ||
| Q4 24 | — | $13.7B | ||
| Q3 24 | — | $14.6B | ||
| Q2 24 | $6.9B | $11.4B | ||
| Q1 24 | — | $5.6B |
| Q4 25 | — | $52.6B | ||
| Q3 25 | — | $51.9B | ||
| Q2 25 | $44.8B | $49.0B | ||
| Q1 25 | — | $48.3B | ||
| Q4 24 | — | $46.3B | ||
| Q3 24 | — | $44.5B | ||
| Q2 24 | $39.6B | $43.6B | ||
| Q1 24 | — | $40.4B |
| Q4 25 | — | $136.9B | ||
| Q3 25 | — | $129.5B | ||
| Q2 25 | $112.4B | $117.5B | ||
| Q1 25 | — | $115.1B | ||
| Q4 24 | — | $117.1B | ||
| Q3 24 | — | $117.5B | ||
| Q2 24 | $104.3B | $112.6B | ||
| Q1 24 | — | $105.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $2.9B |
| Free Cash FlowOCF − Capex | — | $1.8B |
| FCF MarginFCF / Revenue | — | 11.1% |
| Capex IntensityCapex / Revenue | — | 6.3% |
| Cash ConversionOCF / Net Profit | — | 0.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | $7.8B | ||
| Q2 25 | — | $3.3B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $3.5B | ||
| Q3 24 | — | $9.3B | ||
| Q2 24 | — | $5.6B | ||
| Q1 24 | — | $3.1B |
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $6.8B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $8.5B | ||
| Q2 24 | — | $4.8B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | 11.1% | ||
| Q3 25 | — | 39.6% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | — | 30.1% | ||
| Q1 24 | — | 14.1% |
| Q4 25 | — | 6.3% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | 8.6% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | — | 4.7% | ||
| Q2 24 | — | 4.9% | ||
| Q1 24 | — | 5.5% |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.92× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | 0.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZN
Segment breakdown not available.
MRK
| Pharmaceuticalsegment | $8.7B | 53% |
| Keytruda | $4.9B | 30% |
| Other | $2.7B | 16% |
| Janumet | $57.0M | 0% |
| Isentress Isentress HD | $38.0M | 0% |
| Pifeltro | $25.0M | 0% |
| Belsomra | $23.0M | 0% |
| Dificid | $17.0M | 0% |
| Delstrigo | $14.0M | 0% |
| Lagevrio | $12.0M | 0% |
| Pneumovax23 | $4.0M | 0% |
